Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Minerva Surgical to $3 from $20, adjusted for the 1-for-20 reverse stock split, and keeps an Overweight rating on the shares. The firm notes Minerva reported Q3 results that missed on the top-line due to decreasing Miverva ES sales. Symphion, however, delivered robust sales growth and Piper continues to believe it can garner additional market share moving forward.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on UTRS: